Vasopressin for the septic burn patient

Burns

Volumn 33, Issue 4, 2007, Pages 441-451

  Cartotto, Robert ^a   McGibney, Kieron ^a   Smith, Terry ^a   Abadir, Amir ^a  

^a Ross Tilley Burn Centre   (Canada)

Author keywords

Burns; Sepsis; Septic shock; Vasopressin

Indexed keywords

NORADRENALIN; VASOPRESSIN;

ADULT; AGED; ARTICLE; BURN; BURN PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; HEART RATE; HUMAN; MEAN ARTERIAL PRESSURE; NECROSIS; PERIPHERAL ISCHEMIA; SEPSIS; URINE VOLUME;

ADULT; BLOOD PRESSURE; BURNS; GRAFT SURVIVAL; HEART RATE; HEMOSTATICS; HOSPITAL MORTALITY; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SEPSIS; SKIN TRANSPLANTATION; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 34247844253     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.burns.2006.08.012     Document Type: Article

References (56)

1. Dellinger R.P., Carlet J., Masur H., Gerlach H., Calandra T., Cohen J., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32 (2004) 858-873
2. Linder K.H., Strohmenger H.U., Ensinger H., Hetzel W.D., Ahnefeld F.W., and Georgieff M. Stres hormone response during and after cardiopulmonary resuscitation. Anesthesiology 77 (1992) 662-668
3. Shaller M.D., Nussberger J., and Feihl F. Clinical and hemodynamic correlates of elevated plasma arginine vasopressin levels after acute myocardial infarction. Am J Cardiol 60 (1987) 1178-1180
4. Share L. Role of peripheral receptors in the increased release of vasopressin in response to hemorrhage. Endocrinology 81 (1967) 1140-1146
5. Wilson M.F., Brackett D.J., Hinshaw L.B., Tompkins P., Archer L.T., and Benjamin B.A. Vasopressin release during sepsis and septic shock in baboons and dogs. SGO 153 (1981) 869-872
6. Matsuoka T., and Wisner D.H. Hemodynamic and metabolic effects of vasopressin blockade in endotoxin shock. Surgery 121 (1997) 162-173
7. Landry D.W., Levin H.R., Gallant E.M., Ashton R.C., Seo S., D'Alessandro D., et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95 (1997) 1122-1125
8. Tsuneyoshi I., Yamada H., Kakihana Y., Nakamura M., Nakano Y., and Boyle W.A. Hemodynamic and metabolic effects of low dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29 (2001) 487-493
9. Malay M.B., Ashton R.C., Landry D.W., and Townsend R. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma Inj Infect Crit Care 47 (1999) pp. 699-676
10. Holmes C.L., Walley K.R., Chittock D.R., Lehman T., and Russell J.A. The effects of vasopressin on hemodynamic and renal function in severe septic shock: a case series. Intens Care Med 27 (2001) 1416-1421
11. Dunser M., Mayr A., Ulmer H., Ritsch N., Knotzer H., Pajk W., et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and post cardiotomy shock: a retrospective analysis. Anesth Analg 93 (2001) 7-13
12. Dunser M., Mayt A., Ulmer H., Knotzer H., Sumann G., Pajk W., et al. Arginine vasopressin in advanced vasodilatory shock: a prospective randomized controlled study. Circulation 107 (2003) 2313-2319
13. Patel B., Chittock D., Russell J.A., and Walley K.R. Beneficial effects of short term vasopressin infusion during severe septic shock. Anesthesiology 96 (2002) 576-582
14. Bone R.C., Balk R.A., and Cerra F.B. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101 (1992) 1644-1655
15. Marshall J.C., Cook D.J., Christou N.V., Bernard G.R., Sprung C., and Sibbald W.J. The multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 23 (1995) 1638-1652
16. Forrest P. Vasopressin and shock. Anaesth Intens Care 29 (2001) 463-472
17. Benmansour M., Rainfray M., Paillard F., and Ardaillou R. Metabolic clearance rate of immunoreactive vasopressin in man. Eur J Clin Investig 12 (1982) 475-480
18. Baumann G., and Dingman J. Distribution, blood transport, and degredation of antidiuretic hormone in man. J Clin Investig 57 (1976) 1109-1116
19. Morton J.J., Padfield P.L., and Forsling M.L. A radioimmunoassay for plasma arginine vasopressin in man and dog: application to physiological and pathological states. J. Endocrinol 65 (1975) 411-424
20. Holmes C.L., patel B., Russell J.A., and Walley K.R. Physiology of vasopressin relevant to management of septic shock. Chest 120 (2001) 989-1002
21. Bissett G.W., and Chowdrey H.S. Control of release of vasopressin by neuroendocrine reflexes. Q J Exp Physiol 73 (1988) 811-872
22. Fox A. Vascular vasopressin receptors. Gen Pharmacol 19 (1988) 639-645
23. Hirata Y., Hayakawa H., and Kakoki M. Receptor subtypes for vasopressin-induced release of nitric oxide from rat kidney. Hypertension 29 (1997) 58-64
24. Garcia-Villalon A., Garcia J., Monge L., et al. Regional differences in the arterial response to vasopressin: role of nitric oxide. Br J Pharmacol 118 (1996) 1848-1856
25. Martinez M., Vila J., Aldarosoo M., et al. Relaxation of human isolated mesenteric arteries by vasopressin and desmopressin. Br J Pharmacol 113 (1994) 419-424
26. Suzuki Y., Satoh S., Oyama H., Takayasu M., and Shibuya M. Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo. Stroke 24 (1993) 1049-1053
27. Oyama H., Suzuki Y., Satoh S., et al. Role of nitric oxide in the cerebral vasodilatory responses to vasopressin and oxytocin in dogs. J Cereb Blood Flow Metal 13 (1993) 285-290
28. Katusic Z., Shepherd J., and Vanhoutte P. Vasopressin causes endothelium-dependent relaxations of the canine basilar artery. Circ Res 55 (1984) 575-579
29. Padfield P.L., Brown J.J., Lever A.F., Moron J.J., and Robertson J.I.S. Blood pressure in acute and chronic vasopressin excess. New Engl J Med 304 (1981) 1067-1070
30. Cowley A.W., Switzer S.J., and Guinn M.M. Evidence and quantification of the vasopressin arterial pressure control system in the dog. Circ Res 46 (1980) 58-67
31. Garrard C.S., Kontoyannis D.A., and Piepoli M. Spectral analysis of heart rate variability in the sepsis syndrome. Clin Auton Res 3 (1993) 5-13
32. Ebert T., Cowley A., and Skelton M. Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man. J Clin Invest 77 (1986) 1136-1142
33. Boyle Q., and Segel L. Direct cardiac effects of vasopressin and their reversal by a vascular antagonist. Am J Physiol 251 (1986) H734-H741
34. Liard J. Vasopressin in cardiovascular control: role of circulating vasopressin. Clin Sci 67 (1984) 473-484
35. Evora P., pearson P., and Schaff H. Arginine vasopressin induces endothelium-dependant vasodilation of the pulmonary artery V1 receptor mediated production of nitric oxide. Chest 103 (1993) 1241-1245
36. Sharshar T., Blanchard A., Paillard M., Raphael J.C., Gajdos P., and Annanna D. Circulating vasopressin levels in septic shock. Crit Care Med 31 (2003) 1752-1758
37. Morales M.D., Madigan J., Cullinane S., et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 100 (1999) 226-229
38. Landry D.W., Levin H.R., Gallant M., et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25 (1997) 1279-1282
39. Guzman J.A., Rosado A.E., and Kruse J.A. Vasopressin vs. norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects. J Appl Physiol 95 (2003) 803-809
40. Edwards R.M., Trizna W., and Kinter L.B. Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 256 (1989) F274-F278
41. McVicar A.J. Dose-response effects of pressor dose of arginine vasopressin on renal hemodynamics in the rat. J Physiol 404 (1988) 535-546
42. Harrison-Bernard L.M., and Carmines P.K. Juxtamedullary microvascular responses to arginine vasopressin in the rat kidney. Am J Physiol 267 (1994) F249-F256
43. Quayle J.M., Nelson M.T., and Standen N.B. ATP sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 77 (1997) 1165-1232
44. Landry D.W., and Olivier J.A. The pathogenesis of vasodilatory shock. New Engl J Med 345 (2001) 588-595
45. Titheradge M.A. Nitric oxide in septic shock. Biochim Biophys Acta 1411 (1999) 435-437
46. Umino T., Kusano E., and Muto S. AVP inhbits LPS and IL 1β stimulated NO and c-GMP via V1 receptor in cultured rat mesangial cells. Am J Physiol 276 (1999) F431-F433
47. Bolotina V.M., Najibi S., Palacino J.J., Pagano P.J., and Cohen R.A. Nitric oxide directly activates calcium dependant potassium channels in vascular smooth muscle. Nature 368 (1994) 850-853
48. Archer S.L., Huang J.M.C., Hampl V., Nelson D.P., Shultz P.J., and Weir E.K. Nitic oxide and c-GMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by c-GMP dependent protein kinase. Proc Natl Acad Sci USA 91 (1994) 7583-7587
49. Day T.A., Randle J.C., and Renaud L.P. Opposing α and β adrenergic mechanisms mediate dose-dependent actions of norepinephrine on supraoptic vasopressin neurons in vivo. Brain Res 358 (1985) 171-179
50. Wakatsuki T., Nakaya Y., and Inoue I. Vasopressin modulates potassium channel activities of cultured smooth muscle from porcine coronary artery. Am J Physiol 263 (1992) H491-H496
51. Nimbi P., Whitman M., Gessner G., Aiyar N., and Crooke S.T. Vasopressin mediated inhibition of atrial natiuretic factor stimulated cGMP accumulation in established smooth muscle cell line. Proc Natl Acad Sci USA 83 (1986) 8492-8495
52. Beale R.J., Hollenberg S.M., Vincent J.L., and Parrillo J.E. Vasopressor and inotropic support in septic shock: an evidence based review. Crit Care Med 32 (2004) S455-S465
53. Klinzing S., Simon M., Reinhart K., Bredle D., and Meier-Hellmann A. High dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 31 (2003) 2646-2650
54. Thomas T.K. Cutaneous manifestations of intravenous vasopressin therapy. Am J Gastroenterol 80 (1985) 704-705
55. Greenwald R.A., Rheingold O.J., and Chiprut R.O. Local gangrene: a complication of peripheral pitressin therapy for bleeding esophageal varices. Gastroenterology 74 (1978) 744-746
56. Dunser M., Mayr A., Tur A., Pajk W., Barbara F., Knotzer H., et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 31 (2003) 1394-1398